FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:BPTF-PEBP1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: BPTF-PEBP1
FusionPDB ID: 10095
FusionGDB2.0 ID: 10095
HgeneTgene
Gene symbol

BPTF

PEBP1

Gene ID

2186

5037

Gene namebromodomain PHD finger transcription factorphosphatidylethanolamine binding protein 1
SynonymsFAC1|FALZ|NEDDFL|NURF301HCNP|HCNPpp|HEL-210|HEL-S-34|HEL-S-96|PBP|PEBP|PEBP-1|RKIP
Cytomap

17q24.2

12q24.23

Type of geneprotein-codingprotein-coding
Descriptionnucleosome-remodeling factor subunit BPTFbromodomain and PHD domain transcription factorbromodomain and PHD finger-containing transcription factorfetal Alz-50 clone 1 proteinfetal Alz-50 reactive clone 1fetal Alzheimer antigennucleosome remodeling fphosphatidylethanolamine-binding protein 1Raf kinase inhibitory proteinepididymis luminal protein 210epididymis secretory protein Li 34epididymis secretory protein Li 96hippocampal cholinergic neurostimulating peptideneuropolypeptide h3prostatic bi
Modification date2020031320200327
UniProtAcc

Q12830

Main function of 5'-partner protein: FUNCTION: Histone-binding component of NURF (nucleosome-remodeling factor), a complex which catalyzes ATP-dependent nucleosome sliding and facilitates transcription of chromatin. Specifically recognizes H3 tails trimethylated on 'Lys-4' (H3K4me3), which mark transcription start sites of virtually all active genes. May also regulate transcription through direct binding to DNA or transcription factors.
.
Ensembl transtripts involved in fusion geneENST idsENST00000306378, ENST00000321892, 
ENST00000335221, ENST00000424123, 
ENST00000577770, 
ENST00000542939, 
ENST00000261313, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score27 X 21 X 13=73716 X 5 X 4=120
# samples 427
** MAII scorelog2(42/7371*10)=-4.1333991254172
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(7/120*10)=-0.777607578663552
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: BPTF [Title/Abstract] AND PEBP1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: BPTF [Title/Abstract] AND PEBP1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)BPTF(65960520)-PEBP1(118575844), # samples:1
Anticipated loss of major functional domain due to fusion event.BPTF-PEBP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BPTF-PEBP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BPTF-PEBP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BPTF-PEBP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneBPTF

GO:0000122

negative regulation of transcription by RNA polymerase II

10727212

HgeneBPTF

GO:0006338

chromatin remodeling

14609955



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:65960520/chr12:118575844)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across BPTF (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across PEBP1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000335221BPTFchr1765960520+ENST00000261313PEBP1chr12118575844+967484646188922943
ENST00000321892BPTFchr1765960520+ENST00000261313PEBP1chr12118575844+1010388936193213086
ENST00000306378BPTFchr1765960520+ENST00000261313PEBP1chr12118575844+972485146089422960
ENST00000424123BPTFchr1765960520+ENST00000261313PEBP1chr12118575844+91967986084142804

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000335221ENST00000261313BPTFchr1765960520+PEBP1chr12118575844+0.0004725720.99952745
ENST00000321892ENST00000261313BPTFchr1765960520+PEBP1chr12118575844+0.0004315590.9995684
ENST00000306378ENST00000261313BPTFchr1765960520+PEBP1chr12118575844+0.0004011960.9995988
ENST00000424123ENST00000261313BPTFchr1765960520+PEBP1chr12118575844+0.0004314610.9995685

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for BPTF-PEBP1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
BPTFchr1765960520PEBP1chr1211857584479862655LTPLTEKDYEGLKRVLRSLQVKNRPT
BPTFchr1765960520PEBP1chr1211857584484642794LTPLTEKDYEGLKRVLRSLQVKNRPT
BPTFchr1765960520PEBP1chr1211857584485142811LTPLTEKDYEGLKRVLRSLQVKNRPT
BPTFchr1765960520PEBP1chr1211857584488932937LTPLTEKDYEGLKRVLRSLQVKNRPT

Top

Potential FusionNeoAntigen Information of BPTF-PEBP1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
BPTF-PEBP1_65960520_118575844.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:05KRVLRSLQV0.99990.82131221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:02KRVLRSLQV0.99990.55051221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:04KRVLRSLQV0.99990.75741221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:07KRVLRSLQV0.99980.63621221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B14:02DYEGLKRVL0.99580.5622716
BPTF-PEBP1chr1765960520chr121185758448514HLA-B14:01DYEGLKRVL0.99580.5622716
BPTF-PEBP1chr1765960520chr121185758448514HLA-B14:01KRVLRSLQV0.97160.81641221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B14:02KRVLRSLQV0.97160.81641221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B13:02KDYEGLKRV0.90930.6488615
BPTF-PEBP1chr1765960520chr121185758448514HLA-B52:01KDYEGLKRV0.090.936615
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:14KRVLRSLQV0.99990.82411221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:03KRVLRSLQV0.99360.84541221
BPTF-PEBP1chr1765960520chr121185758448514HLA-C07:05KRVLRSLQV0.9470.9641221
BPTF-PEBP1chr1765960520chr121185758448514HLA-C07:27KRVLRSLQV0.94580.95421221
BPTF-PEBP1chr1765960520chr121185758448514HLA-C07:95KRVLRSLQV0.93290.75551221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B14:03DYEGLKRVL0.67650.6335716
BPTF-PEBP1chr1765960520chr121185758448514HLA-B15:04GLKRVLRSL0.58550.92351019
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:14KRVLRSLQVK0.99980.88291222
BPTF-PEBP1chr1765960520chr121185758448514HLA-B18:03YEGLKRVL0.99570.9123816
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:08KRVLRSLQV0.99990.75151221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:10KRVLRSLQV0.99990.86081221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:09KRVLRSLQV0.99980.80591221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:06KRVLRSLQV0.99970.7531221
BPTF-PEBP1chr1765960520chr121185758448514HLA-C06:08KRVLRSLQV0.98320.98951221
BPTF-PEBP1chr1765960520chr121185758448514HLA-A02:03GLKRVLRSL0.9780.80241019
BPTF-PEBP1chr1765960520chr121185758448514HLA-C07:01KRVLRSLQV0.96660.74141221
BPTF-PEBP1chr1765960520chr121185758448514HLA-C07:04KRVLRSLQV0.64770.95471221
BPTF-PEBP1chr1765960520chr121185758448514HLA-C07:22KRVLRSLQV0.63240.71951221
BPTF-PEBP1chr1765960520chr121185758448514HLA-C14:02DYEGLKRVL0.52090.8956716
BPTF-PEBP1chr1765960520chr121185758448514HLA-C14:03DYEGLKRVL0.52090.8956716
BPTF-PEBP1chr1765960520chr121185758448514HLA-C06:06KRVLRSLQV0.31310.98651221
BPTF-PEBP1chr1765960520chr121185758448514HLA-C06:02KRVLRSLQV0.13750.99231221
BPTF-PEBP1chr1765960520chr121185758448514HLA-C06:17KRVLRSLQV0.13750.99231221
BPTF-PEBP1chr1765960520chr121185758448514HLA-B27:10KRVLRSLQVK0.99970.9051222

Top

Potential FusionNeoAntigen Information of BPTF-PEBP1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
BPTF-PEBP1_65960520_118575844.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1105EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1106YEGLKRVLRSLQVKN823
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1108EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1108TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1108LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1111EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1111TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1111LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1114EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1114TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1114LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1119EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1119TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1119LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1120EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1120TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1120LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1127EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1131EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1131TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1131LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1132EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1145EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1145TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1145LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1147YEGLKRVLRSLQVKN823
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1154YEGLKRVLRSLQVKN823
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1164EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1164TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1164LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1168EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1168TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1168LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1172EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1172TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1172LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1172KDYEGLKRVLRSLQV621
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1173EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1173TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1173LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1179EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1182EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1186EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1186TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1186LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1204LKRVLRSLQVKNRPT1126
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1209LKRVLRSLQVKNRPT1126
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1302EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1302TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1302LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1316EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1316TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1316LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1323EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1323TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1323LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1326EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1329EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1329TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1329LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1334EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1334TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1334LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1336EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1336TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1339EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1339TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1339LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1341EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1341TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1341LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1356EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1356TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1356LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1363EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1363TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1363LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1373EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1373TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1373LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1374EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1374TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1374LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1382EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1382TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1382LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1385EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1385TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1385LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1386EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1386TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1386LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1386KDYEGLKRVLRSLQV621
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1396EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1396TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1396LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1397EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1397TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1397LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1399EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1399TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1399LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1402EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1403EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1403TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1403LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1424EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1427EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1430EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1430TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1430LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1440EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1440TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1440LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1441EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1442EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1467EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1467TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1467LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1477EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1477TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1477LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1489EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1494EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1498EKDYEGLKRVLRSLQ520
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1498TEKDYEGLKRVLRSL419
BPTF-PEBP1chr1765960520chr121185758448514DRB1-1498LTEKDYEGLKRVLRS318
BPTF-PEBP1chr1765960520chr121185758448514DRB5-0205LKRVLRSLQVKNRPT1126

Top

Fusion breakpoint peptide structures of BPTF-PEBP1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4173KDYEGLKRVLRSLQBPTFPEBP1chr1765960520chr121185758448514

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of BPTF-PEBP1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B52:013W394173KDYEGLKRVLRSLQ-7.90165-7.90165
HLA-B44:053DX84173KDYEGLKRVLRSLQ-5.81679-5.81679

Top

Vaccine Design for the FusionNeoAntigens of BPTF-PEBP1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
BPTF-PEBP1chr1765960520chr121185758441019GLKRVLRSLTCCTTACAGGTTAAGAATAGACCCACC
BPTF-PEBP1chr1765960520chr121185758441221KRVLRSLQVCAGGTTAAGAATAGACCCACCAGCATT
BPTF-PEBP1chr1765960520chr121185758441222KRVLRSLQVKCAGGTTAAGAATAGACCCACCAGCATTTCG
BPTF-PEBP1chr1765960520chr12118575844615KDYEGLKRVAGGGTGCTCCGTTCCTTACAGGTTAAG
BPTF-PEBP1chr1765960520chr12118575844716DYEGLKRVLGTGCTCCGTTCCTTACAGGTTAAGAAT
BPTF-PEBP1chr1765960520chr12118575844816YEGLKRVLCTCCGTTCCTTACAGGTTAAGAAT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
BPTF-PEBP1chr1765960520chr121185758441126LKRVLRSLQVKNRPTTTACAGGTTAAGAATAGACCCACCAGCATTTCGTGGGATGGTCTT
BPTF-PEBP1chr1765960520chr12118575844318LTEKDYEGLKRVLRSGGGTTGAAGAGGGTGCTCCGTTCCTTACAGGTTAAGAATAGACCC
BPTF-PEBP1chr1765960520chr12118575844419TEKDYEGLKRVLRSLTTGAAGAGGGTGCTCCGTTCCTTACAGGTTAAGAATAGACCCACC
BPTF-PEBP1chr1765960520chr12118575844520EKDYEGLKRVLRSLQAAGAGGGTGCTCCGTTCCTTACAGGTTAAGAATAGACCCACCAGC
BPTF-PEBP1chr1765960520chr12118575844621KDYEGLKRVLRSLQVAGGGTGCTCCGTTCCTTACAGGTTAAGAATAGACCCACCAGCATT
BPTF-PEBP1chr1765960520chr12118575844823YEGLKRVLRSLQVKNCTCCGTTCCTTACAGGTTAAGAATAGACCCACCAGCATTTCGTGG

Top

Information of the samples that have these potential fusion neoantigens of BPTF-PEBP1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCABPTF-PEBP1chr1765960520ENST00000306378chr12118575844ENST00000261313TCGA-GM-A2D9-01A

Top

Potential target of CAR-T therapy development for BPTF-PEBP1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to BPTF-PEBP1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to BPTF-PEBP1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource